The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Prelinical investigation with the anti-p53 drug, APR-246.
 
Naoise C Synnott
No Relationships to Disclose
 
Alyson M. Murray
No Relationships to Disclose
 
Norma O'Donovan
Research Funding - Eisai
 
John Crown
Honoraria - Bayer; Eisai; Genomic Health; New Oncology; Novartis; Pfizer; Teva
Consulting or Advisory Role - Bayer; Eisai; Genomic Health; New Oncology; Novartis; Pfizer; Teva
Speakers' Bureau - Genomic Health; Pfizer
Research Funding - Boehringer Ingelheim; Eisai; GlaxoSmithKline; Roche/Genentech
 
Michael J. Duffy
No Relationships to Disclose